This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Beta-Cell Function After Near-Normalisation of Blood Glucose

This study has been completed.
Information provided by:
Hvidovre University Hospital Identifier:
First received: January 16, 2008
Last updated: February 11, 2008
Last verified: January 2008
The incretin effect is attenuated in patients with type 2 diabetes mellitus partly due to impaired potentiation of beta-cell responsiveness to glucose by glucose dependent insulinotropic polypeptide and glucagon-like peptide-1 respectively. The aim of the present study was to investigate whether 4 weeks of near-normalization of blood glucose could improve the insulin responses to GIP and GLP-1 in patients with type 2 diabetes.

Condition Intervention
Type 2 Diabetes Drug: glucagon-like peptide-1, Drug: glucose dependent insulinotropic polypeptide Drug: Saline

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: Four Weeks of Near Normalisation of Blood Glucose Improves the Insulin Response to GLP-1 and GIP in Patients With Type 2 Diabetes

Resource links provided by NLM:

Further study details as provided by Hvidovre University Hospital:

Primary Outcome Measures:
  • 2.phase insulin response measured as incremental area under the curve from 10-120 minutes [ Time Frame: 2 hours ]

Secondary Outcome Measures:
  • 2.phase insulin response measured as incremental area under the curve from 10-120 minutes, after 4 weeks of insulin treatment [ Time Frame: 2 hours ]

Enrollment: 8
Study Start Date: October 2006
Study Completion Date: May 2007
Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GLP-1 Drug: glucagon-like peptide-1,
GLP-1:continuous infusion of ½ pmol/kg/min for a total time of 120 minutes.
Experimental: GIP Drug: glucose dependent insulinotropic polypeptide
continuous infusion of GIP (1½ pmol/kg/min) for 120 min.
Placebo Comparator: saline Drug: Saline
continuous infusion of Saline for 120 min


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 18-70 years
  • Type 2 diabetes diagnosed after 30 years of age
  • BMI > 25

Exclusion Criteria:

  • Severe complications to diabetes
  • Abnormal liver and kidney function
  • Haemoglobin below the lower limit
  • Macroalbuminuria
  • Systemic disease
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00612950

Dept. of Endocrinology, Hvidovre Hospital
Copenhagen, Denmark
Sponsors and Collaborators
Hvidovre University Hospital
Principal Investigator: Patricia V Højberg, MD, PHD University Hospital Hvidovre
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Patricia Verdugo Højberg/ MD, PHD, Kettegaard Alle 30, 2650 Hvidovre Identifier: NCT00612950     History of Changes
Other Study ID Numbers: KA 03005
Study First Received: January 16, 2008
Last Updated: February 11, 2008

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Gastric Inhibitory Polypeptide
Glucagon-Like Peptide 1
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Incretins processed this record on August 18, 2017